Go back to News
NEWS
GA_P advises Uriach on the sale of its generics and b2b business to MCH
14 September, 2021
Gómez-Acebo & Pombo has advised Grupo J. Uriach on the sale of its B2B business to the investment fund MCH, with the participation of a group of investors. With this transaction, Uriach completes the process of divestment in the pharmaceutical sector and sale of generics, to focus on its strategic business plan in the Consumer Healthcare (CHC) sector.
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
The divestment involves the sale of the two production plants owned by Grupo J. Uriach Group in Spain. On the one hand, the chemical plant (Urquima) located in Sant Fost de Campsentelles and the pharmaceutical plant in Palau-Solità i Plegamans, which currently allocates 75-80% of its production to the B2B business. The rest of this production is dedicated to CHC, which will continue to be made at this plant through a long-term strategic production agreement between Grupo J. Uriach and the new company owned by the new company. Uriach Group and the new company owned by MCH. This area has a forecast turnover of 80 million by the end of 2021. MCH’s objective is to expand its activity through new developments and R&D investment.
The sale agreement is currently subject to the approval of the competition authorities.
Lazard has been the bank advisor leading the transaction and Deloitte has acted as financial advisor.
The GA_P team was formed by Dani Marín, Carolina Posse, Estefanía Fraile and Diana Urrego, partner and associate, respectively, in the Corporate area, Iñigo Igartua and Andrea Díez de Uré, partner and associate in the Competition area, Nuria Vila, of counsel in the Tax area and Begoña Vilar, associate in the Employment area.
See complete article in Cinco Días
Lawyer mentioned
Daniel Marín – Partner
Carolina Posse Van Der Laat – Senior associate
See all lawyers
See less lawyers
Category
Deal
Press contact
Director of Business Development, Marketing and Communications
Director of Business Development, Marketing and Communications
More information about
Gómez-Acebo & Pombo
3 days ago 
PUBLICATION
¡NEW!
European reform of the sustainability reporting regime under Directive (EU) 2026/470: consequences of its non-transposition into domestic law
Directive (EU) 2026/470 (Omnibus I) has been published, limiting the obligation to prepare a sustainability report to public-interest entities with more than 1,000 employees and a net turnover of more than €450 million during the preceding financial year, as well as to parent companies of a large group that exceed these figures on a consolidated basis. The Directive amends the audit directive, the accounting directive, the corporate sustainability reporting directive (CSRD) and the corporate sustainability due diligence directive (CSDDD).
¡NEW! 
PUBLICATION
2 days ago
Uncertificated share pledge creation, enforceability and avoidance (Supreme Court Judgment no.183/2026 of 10 February)
In Judgment no. 183/2026, of 10 February, the Supreme Court analysed the requirements for the validity and enforceability of an uncertificated registered share pledge and examined the conditions for its avoidance in the context of insolvency proceedings.
2 days ago
PUBLICATION
One week ago
The long arm of the Unified Patent Court based on the "event giving rise to the infringement" and considerations on the application of lex loci protectionis
This paper analyses the decision of the Mannheim Local Division of 2 October 2025, where the Unified Patent Court (UPC) justifies its jurisdiction on the basis of shipment of products from a UPC territory by company listed as authorized representative in the EC and UK markets as event giving rise to damage. Furthermore, although the applicable law with regard to the infringement of the European patent validated in States that are not party to the Agreement on a Unified Patent Court is the national law of those States, with regard to the scope of patent protection, the UPC imposes on the defendant—unduly—the burden of proving the specifics of national law.
One week ago
PUBLICATION
03 Mar, 2026
Legal doctrine of the UPC’s Court of Appeal on the patent invalidity defence: is the way in which the ‘long arm’ is applied compatible with the UPC's own Rules of Procedure?
The Court of Appeal of the Unified Patent Court has ruled that a patent invalidity defence cannot be raised before the Unified Patent Court, with only a counterclaim being possible. This calls into question the way in which the ‘long arm’ is being applied with regard to European patents validated in States that are not party to the Agreement on a Unified Patent Court (UPCA), whether or not they are members of the European Union, since no counterclaim for revocation or plea of invalidity as a defence can be filed or raised with regard to such patents. This raises significant doubts about the compatibility of how the ‘long arm’ is applied in the Unified Patent Court system, given its own Rules of Procedure.
03 Mar, 2026
PUBLICATION
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026
PUBLICATION
09 Feb, 2026
Notarial enforcement of pledges. Is Article 1872 of the Civil Code mandatory? In what sense?
The clause agreed upon must comply, for greater certainty, with the provisions of the new judicial enforcement procedure. It will be necessary to agree on an appraised value, which is not required in Article 1872 CC, because otherwise the award would be similar to a ‘forfeiture proviso’ (pactum commissorium), which the Civil Code neutralised with the drastic imposition of extinguishment of the debt in its entirety.
09 Feb, 2026
PUBLICATION
06 Feb, 2026
Automotive and Sustainable Mobility No. 29
Summary of legislative and jurisprudential developments relating to the automotive sector.
06 Feb, 2026
PUBLICATION
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICATION
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026